This study aimed to evaluate the relationships between regional muscle mass, fat mass (FM), and circulating adipokines with BMD

GLP-1 and the Gut Microbiome: A Bidirectional Story The relevance of probiotics during GLP-1 use is grounded in real biology that goes beyond just "gut health." A 2026 narrative review in the British Journal of Clinical Pharmacology examined the bidirectional relationship between GLP-1 RAs and the gut microbiome.[4] The review documents that: GLP-1 RAs themselves modify gut microbial composition, with several studies showing shifts in the Firmicutes/Bacteroidetes ratio and increased abundance of certain Bifidobacterium and Lactobacillus species during treatment The gut microbiome in turn produces metabolites (short-chain fatty acids, secondary bile acids) that stimulate endogenous GLP-1 secretion Microbiome composition may influence inter-individual response to GLP-1 therapy through inflammation, insulin sensitivity, and metabolic pathways The implication for probiotic supplementation: the period during GLP-1 use is one of meaningful microbial change driven by altered transit, reduced food intake, and direct drug effects

Are prepared for medication-supported approaches under medical supervision
Studies concerning indirect mechanisms linking GLP-1 RAs, to coronary events are not included
The only catch is that she recommends adding in psyllium gradually and with adequate fluid (this part is very important), as combining two agents that slow digestion can increase bloating or fullness if started at higher doses. Godart adds that key benefits often overlooked are psylliums ability to improve bowel regularity and reduce LDL cholesterol, which supports overall cardiometabolic health
J Nepal Med Assoc